Brief: VistaGen Reports Preclinical Data Supporting Itruvone (Ph10) Nasal Spray’S Potential Antidepressant Activity Via Peripheral Nasal Neurons Without Entry Into The Brain
17/07/2023 14:08
July 17 (Reuters) - VistaGen Therapeutics Inc VTGN.O :
* VISTAGEN REPORTS NEW PRECLINICAL DATA SUPPORTING ITRUVONE
(PH10)
NASAL SPRAY’S POTENTIAL ANTIDEPRESSANT ACTIVITY VIA PERIPHERAL
NASAL NEURONS WITHOUT ENTRY INTO THE BRAIN
Source text for Eikon: ID:nBw6MwnNfa
Further company coverage: VTGN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors